The Modulated Role of on Eosinophils in Psychiatric Disorders After Cannabis Cessation

Overview

Journal Pathogens

Date 2023 Nov 25

PMID 38003797

Authors

Bruno Romeo

Valentine Lestra

Catherine Martelli

Ammar Amirouche

Amine Benyamina

Nora Hamdani

Affiliations

Soon will be listed here.

Abstract

The aim of our study was to evaluate the impact of status on eosinophils count (EOS), the eosinophil-to-lymphocyte ratio (ELR), and the eosinophil-to-neutrophil-to-lymphocytes ratio (ENLR) before and after cannabis cessation in patients with psychiatric disorders. One hundred and eighty-eight patients were included in the study. , EOS, ELR, ENLR, and urinary cannabis were measured at baseline and after 4 weeks of cannabis cessation. Highest levels and increase of PNE ( = 0.02), ENLR levels ( = 0.031) and highest level of ELR ( = 0.03) were found in patients after cannabis cessation only in patients positive for serology (Toxo+ group). At four weeks, significant interactions between cannabis and status for EOS ( = 0.038), and for ENLR ( = 0.043) levels were found, as well as for the evolution between baseline and 4 weeks for ENLR level ( = 0.049). After cannabis cessation, we found a positive correlation between negative symptoms and EOS levels at 4 weeks in the Toxo+ group. This study shows that the increase of inflammation after cannabis cessation might be modulated by seropositivity status in patients after cannabis cessation.

References

Hamdani N, Daban-Huard C, Lajnef M, Richard J, Delavest M, Godin O . Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013; 148(2-3):444-8. DOI: 10.1016/j.jad.2012.11.034. View

Aceves S, Ackerman S . Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am. 2009; 29(1):197-211, xiii-xiv. PMC: 2665721. DOI: 10.1016/j.iac.2008.10.003. View

De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V . Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003; 2:5. PMC: 194767. DOI: 10.1186/1476-511X-2-5. View

Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

Corsi-Zuelli F, Marques L, da Roza D, Loureiro C, Shuhama R, Di Forti M . The independent and combined effects of cannabis use and systemic inflammation during the early stages of psychosis: exploring the two-hit hypothesis. Psychol Med. 2021; :1-11. DOI: 10.1017/S0033291721000726. View

Muller N . Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. Schizophr Bull. 2018; 44(5):973-982. PMC: 6101562. DOI: 10.1093/schbul/sby024. View

Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt P, Wolf S . The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 2006; 49(1):67-79. DOI: 10.1016/j.neuron.2005.11.027. View

Hamdani N, Daban-Huard C, Lajnef M, Gadel R, Le Corvoisier P, Delavest M . Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. J Affect Disord. 2015; 179:161-6. DOI: 10.1016/j.jad.2015.03.038. View

Sutterland A, Fond G, Kuin A, Koeter M, Lutter R, van Gool T . Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. 2015; 132(3):161-79. DOI: 10.1111/acps.12423. View

10.

Kuang F . Approach to Patients with Eosinophilia. Med Clin North Am. 2019; 104(1):1-14. PMC: 7089574. DOI: 10.1016/j.mcna.2019.08.005. View

11.

Barbosa P, Tofoli L, Bogenschutz M, Hoy R, Berro L, Marinho E . Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca. Front Psychiatry. 2018; 9:136. PMC: 5928846. DOI: 10.3389/fpsyt.2018.00136. View

12.

Goldsmith D, Rapaport M . Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Front Psychiatry. 2020; 11:46. PMC: 7044128. DOI: 10.3389/fpsyt.2020.00046. View

13.

Johnson S, Johnson P . Toxoplasmosis: Recent Advances in Understanding the Link Between Infection and Host Behavior. Annu Rev Anim Biosci. 2020; 9:249-264. DOI: 10.1146/annurev-animal-081720-111125. View

14.

Cossu G, Preti A, Gyppaz D, Gureje O, Carta M . Association between toxoplasmosis and bipolar disorder: A systematic review and meta-analysis. J Psychiatr Res. 2022; 153:284-291. DOI: 10.1016/j.jpsychires.2022.07.013. View

15.

Howes O, McCutcheon R . Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 2017; 7(2):e1024. PMC: 5438023. DOI: 10.1038/tp.2016.278. View

16.

Melamede R . Parasitic brain infection, endocannabinoids, and schizophrenia. Med Hypotheses. 2008; 72(2):220-2. DOI: 10.1016/j.mehy.2008.08.025. View

17.

Miller B, Buckley P, McEvoy J . Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res. 2017; 195:275-282. DOI: 10.1016/j.schres.2017.08.027. View

18.

Fond G, Boyer L, Schurhoff F, Berna F, Godin O, Bulzacka E . Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. Schizophr Res. 2018; 201:373-380. DOI: 10.1016/j.schres.2018.05.007. View

19.

Hunt G, Malhi G, Cleary M, Lai H, Sitharthan T . Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis. J Affect Disord. 2016; 206:331-349. DOI: 10.1016/j.jad.2016.07.011. View

20.

Hunt G, Large M, Cleary M, Lai H, Saunders J . Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018; 191:234-258. DOI: 10.1016/j.drugalcdep.2018.07.011. View